Metabolic fingerprint of ischaemic cardioprotection: Importance of the malateaspartate shuttle

Cardiovascular Research

Volumn 91, Issue 3, 2011, Pages 382-391

  Nielsen, Torsten Toftegaard ^a,b   Støttrup, Nicolaj Brejnholt ^a,b   Løfgren, Bo ^a,b   Bøtker, Hans Erik ^a,b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Carbohydrate metabolism; Infarct size; Ischaemia; Malateaspartate shuttle; Reperfusion

Indexed keywords

AMINOOXYACETIC ACID; ASPARTIC ACID; GLUTAMIC ACID; MALIC ACID; TRICARBOXYLIC ACID;

CALCIUM HOMEOSTASIS; CELL FUNCTION; CYTOSOL; ENERGY METABOLISM; GLUCOSE METABOLISM; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEMODYNAMICS; HUMAN; MITOCHONDRIAL ENERGY TRANSFER; MITOCHONDRIAL RESPIRATION; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY CHAIN; REVIEW;

ANIMALS; ASPARTIC ACID; CALCIUM; ENERGY METABOLISM; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALATES; MITOCHONDRIA, HEART; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM;

EID: 79960808907     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvr051     Document Type: Review

References (146)

1. Ingwall JS. ATP and the Heart. Boston: Kluwer Academic Publishers; 2002.
2. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;1:785-789.
3. Depre C, Vanoverschelde JL, Taegtmeyer H. Glucose for the heart. Circulation 1999; 99:578-588. (Pubitemid 29061876)
4. Thomassen A, Bagger JP, Nielsen TT, Henningsen P. Altered global myocardial substrate preference at rest and during pacing in coronary artery disease with stable angina pectoris. Am J Cardiol 1988;62:686-693.
5. Opie LH, Lopaschuk GD. Fuels, aerobic and anaerobic metabolism. In: Opie LH, ed. Heart Physiology, from Cell to Circulation. Philadelphia: Lippincott, Williams & Wilkins; 2004:306.
6. van der Horst IC, Zijlstra F, van 't Hof AW, Doggen CJ, de Boer MJ, Suryapranata H et al. Glucose-insulin-potassium infusion in patients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial. J Am Coll Cardiol 2003;42:784-791. (Pubitemid 37059733)
7. Mehta SR, Yusuf S, Diaz R, Zhu J, Pais P, Xavier D et al. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA 2005;293:437-446.
8. Malmberg K, Ryden L, Wedel H, Birkeland K, Bootsma A, Dickstein K et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005;26:650-661. (Pubitemid 40516876)
9. Malmberg K, Norhammar A, Wedel H, Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999;99:2626-2632. (Pubitemid 29237448)
10. Wiggers H, Norrelund H, Nielsen SS, Andersen NH, Nielsen-Kudsk JE, Christiansen JS et al. Influence of insulin and free fatty acids on contractile function in patients with chronically stunned and hibernating myocardium. Am J Physiol Heart Circ Physiol 2005;289:H938-H946. (Pubitemid 41129413)
11. Halbirk M, Nürrelund H, Müller N, Schmitz O, Gützsche L, Nielsen R et al. Suppression of circulating free fatty acids with acipimox in chronic heart failure patients changes whole body metabolism but does not affect cardiac function. Am J Physiol Heart Circ Physiol 2010;299:H1220-H1225.
12. Beadle RM, Frenneaux M. Modification of myocardial substrate utilisation: a new therapeutic paradigm in cardiovascular disease. Heart 2010;96:824-830.
13. Lewandowski ED, White LT. Pyruvate dehydrogenase influences postischemic heart function. Circulation 1995;91:2071-2079.
14. Hermann HP, Pieske B, Schwarzmuller E, Keul J, Just H, Hasenfuss G. Haemodynamic effects of intracoronary pyruvate in patients with congestive heart failure: an open study. Lancet 1999;353:1321-1323. (Pubitemid 29178783)
15. Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L et al. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 2005;112: 3280-3288. (Pubitemid 43739373)
16. Neubauer S. The failing heart-an engine out of fuel. N Engl J Med 2007;356: 1140-1151. (Pubitemid 46425598)
17. Madrazo JA, Kelly DP. The PPAR trio: regulators of myocardial energy metabolism in health and disease. J Mol Cell Cardiol 2008;44:968-975.
18. Borst P. The anaerobic oxidation of reduced diphosphopyridine nucleotide formed by glycolysis in Erlich ascites-tumour cells. Biochim Biophys Acta 1962;57:270-282.
19. Safer B. The metabolic significance of the malate-aspartate cycle in heart. Circ Res 1975;37:527-533.
20. LaNoue KF, Schoolwerth AC. Metabolite transport in mitochondria. Annu Rev Biochem 1979;48:871-922.
21. Stttrup NB, Lfgren B, Birkler RD, Nielsen JM, Wang L, Caldarone CA et al. Inhibition of the malate-aspartate shuttle by preischaemic aminooxyacetate loading of the heart induces cardioprotection. Cardiovasc Res 2010; 88:257-266.
22. Lüfgren B, Povlsen JA, Rasmussen LE, Stüttrup NB, Solskov L, Krarup PM et al. Amino acid transamination is crucial for ischaemic cardioprotection in normal and preconditioned isolated rat hearts-focus on L-glutamate. Exp Physiol 2010;95: 140-152.
23. Halestrap AP, Clarke SJ, Khaliulin I. The role of mitochondria in protection of the heart by preconditioning. Biochim Biophys Acta 2007;1767:1007-1031. (Pubitemid 47101788)
24. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007;357: 1121-1135.
25. Di Lisa F, Canton M, Carpi A, Kaludercic N, Menabo R, Menazza S et al. Mitochondrial Injury and Protection in Ischemic Pre- and Postconditioning. Antioxid Redox Signal 2011;14:881-891.
26. Boengler K, Heusch G, Schulz R. Mitochondria in postconditioning. Antioxid Redox Signal 2011;14:863-880.
27. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-1136. (Pubitemid 17174962)
28. Granfeldt A, Lefer DJ, Vinten-Johansen J. Protective ischaemia in patients: preconditioning and postconditioning. Cardiovasc Res 2009;83:234-246.
29. Di Lisa F, Bernardi P. Mitochondria and ischemia-reperfusion injury of the heart: fixing a hole. Cardiovasc Res 2006;70:191-199.
30. Argaud L, Gateau-Roesch O, Raisky O, Loufouat J, Robert D, Ovize M. Postconditioning inhibits mitochondrial permeability transition. Circulation 2005;111:194-197. (Pubitemid 40139731)
31. Lehninger AL. Phosphorylation coupled to oxidation of dihydrodiphosphopyridine nucleotide. J Biol Chem 1951;190:345-359.
32. Di Lisa F, Menabo R, Canton M, Barile M, Bernardi P. Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD+ and is a causative event in the death of myocytes in postischemic reperfusion of the heart. J Biol Chem 2001;276:2571-2575.
33. Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev 2008;88:581-609. (Pubitemid 351520088)
34. Hausenloy DJ, Lecour S, Yellon DM. Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin. Antioxid Redox Signal 2011;14:893-907.
35. Pagliaro P, Moro F, Tullio F, Perrelli MG, Penna C. Cardioprotective pathways during reperfusion: focus on redox signaling and other modalities of cell signaling. Antioxid Redox Signal 2011;14:833-850.
36. Lecour S. Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: does it go beyond the RISK pathway? J Mol Cell Cardiol 2009;47:32-40.
37. Chen W, Wetsel W, Steenbergen C, Murphy E. Effect of ischemic preconditioning and PKC activation on acidification during ischemia in rat heart. J Mol Cell Cardiol 1996;28:871-880. (Pubitemid 26169298)
38. Mayr M, Liem D, Zhang J, Li X, Avliyakulov NK, Yang JI et al. Proteomic and metabolomic analysis of cardioprotection: interplay between protein kinase C epsilon and delta in regulating glucose metabolism of murine hearts. J Mol Cell Cardiol 2009;46:268-277.
39. Rej R. Aminooxyacetate is not an adequate differential inhibitor of aspartate aminotransferase isoenzymes. Clin Chem 1977;23:1508-1509.
40. Beeckmans S, Kanarek L. Demonstration of physical interactions between consecutive enzymes of the citric acid cycle and of the aspartate-malate shuttle. A study involving fumarase, malate dehydrogenase, citrate synthesis and aspartate aminotransferase. Eur J Biochem 1981;117:527-535.
41. Palmieri L, Pardo B, Lasorsa FM, del Arco A, Kobayashi K, Iijima M et al. Citrin and aralar1 are Ca(2+)-stimulated aspartate/glutamate transporters in mitochondria. EMBO J 2001;20:5060-5069. (Pubitemid 32910902)
42. Taylor SW, Fahy E, Zhang B, Glenn GM, Warnock DE, Wiley S et al. Characterization of the human heart mitochondrial proteome. Nat Biotechnol 2003;21:281-286. (Pubitemid 36314812)
43. Ralphe JC, Segar JL, Schutte BC, Scholz TD. Localization and function of the brain excitatory amino acid transporter type 1 in cardiac mitochondria. J Mol Cell Cardiol 2004;37:33-41. (Pubitemid 38900526)
44. Ralphe JC, Bedell K, Segar JL, Scholz TD. Correlation between myocardial malate/ aspartate shuttle activity and EAAT1 protein expression in hyper- and hypothyroidism. Am J Physiol Heart Circ Physiol 2005;288:H2521-H2526. (Pubitemid 40604142)
45. Povlsen JA, Lüfgren B, Rasmussen LE, Nielsen JM, Norregaard R, Kristiansen SB et al. Cardioprotective effect of L-glutamate in Obese Type 2 Diabetes MellitusStudies on the isolated perfused Zucker diabetic fatty rat heart. Clin Exp Pharmacol Physiol 2009; 36:892-898.
46. Safer B, Smith CM, Williamson JR. Control of the transport of reducing equivalents across the mitochondrial membrane in perfused rat heart. J Mol Cell Cardiol 1971;2: 111-124.
47. Williamson JR, Jakob A, Refino C. Control of the removal of reducing equivalents from the cytosol in perfused rat liver. J Biol Chem 1971;246:7632-7641.
48. Brand MD, Chappell JB. Glutamate and aspartate transport in rat brain mitochondria. Biochem J 1974;140:205-210.
49. Rognstad R, Katz J. Gluconeogenesis in the kidney cortex. Effects of D-malate and amino-oxyacetate. Biochem J 1970;116:483-491.
50. Eto K, Tsubamoto Y, Terauchi Y, Sugiyama T, Kishimoto T, Takahashi N et al. Role of NADH shuttle system in glucose-induced activation of mitochondrial metabolism and insulin secretion. Science 1999;283:981-985.
51. Barron JT, Gu L, Parrillo JE. Malate-aspartate shuttle, cytoplasmic NADH redox potential, and energetics in vascular smooth muscle. J Mol Cell Cardiol 1998;30: 1571-1579. (Pubitemid 28418647)
52. Burwell LS, Nadtochiy SM, Brookes PS. Cardioprotection by metabolic shut-down and gradual wake-up. J Mol Cell Cardiol 2009;46:804-810.
53. Aldakkak M, Stowe DF, Chen Q, Lesnefsky EJ, Camara AK. Inhibited mitochondrial respiration by amobarbital during cardiac ischaemia improves redox state and reduces matrix Ca2+ overload and ROS release. Cardiovasc Res 2008;77:406-415. (Pubitemid 351197651)
54. Tanaka-Esposito C, Chen Q, Moghaddas S, Lesnefsky EJ. Ischemic preconditioning does not protect via blockade of electron transport. J Appl Physiol 2007;103: 623-628. (Pubitemid 47204982)
55. Bunger R, Glanert S, Sommer O, Gerlach E. Inhibition by (aminooxy)acetate of the malate-aspartate cycle in the isolated working guinea pig heart. Hoppe Seylers Z Physiol Chem 1980;361:907-914. (Pubitemid 11235564)
56. Opie L.H. Effect of fatty acids on contractility and rhythm of the heart. Nature 1970; 227:1055-1056.
57. Gambert S, Vergely C, Filomenko R, Moreau D, Bettaieb A, Opie LH et al. Adverse effects of free fatty acid associated with increased oxidative stress in postischemic isolated rat hearts. Mol Cell Biochem 2006;283:147-152.
58. Gonzalez-Mateos F, Gomez ME, Garcia-Salguero L, Sanchez V, Aragon JJ. Inhibition of glycolysis by amino acids in ascites tumor cells. Specificity and mechanism. J Biol Chem 1993;268:7809-7817. (Pubitemid 23120355)
59. Cooper AJ, Fitzpatrick SM, Ginos JZ, Kaufman C, Dowd P. Inhibition of glutamate-aspartate transaminase by beta-methylene-DL-aspartate. Biochem Pharmacol 1983;32:679-689.
60. Fitzpatrick SM, Cooper AJ, Duffy TE. Use of beta-methylene-D,L-aspartate to assess the role of aspartate aminotransferase in cerebral oxidative metabolism. J Neurochem 1983;41:1370-1383. (Pubitemid 14227451)
61. LaNoue KF, Berkich DA, Conway M, Barber AJ, Hu LY, Taylor C et al. Role of specific aminotransferases in de novo glutamate synthesis and redox shuttling in the retina. J Neurosci Res 2001;66:914-922.
62. Satrustegui J, Pardo B, Del Arco A. Mitochondrial transporters as novel targets for intracellular calcium signaling. Physiol Rev 2007;87:29-67. (Pubitemid 46207712)
63. Balaban RS. The role of Ca(2+) signaling in the coordination of mitochondrial ATP production with cardiac work. Biochim Biophys Acta 2009;1787:1334-1341.
64. Gellerich FN, Gizatullina Z, Trumbeckaite S, Nguyen HP, Pallas T, Arandarcikaite O et al. The regulation of OXPHOS by extramitochondrial calcium. Biochim Biophys Acta 2010;1797:1018-1027.
65. Contreras L, Gomez-Puertas P, Iijima M, Kobayashi K, Saheki T, Satrustegui J. Ca2+ Activation kinetics of the two aspartate-glutamate mitochondrial carriers, aralar and citrin: role in the heart malate-aspartate NADH shuttle. J Biol Chem 2007;282: 7098-7106. (Pubitemid 47093651)
66. Winter CR, Baker RC. L-glutamate-induced changes in intracellular calcium oscillation frequency through non-classical glutamate receptor binding in cultured rat myocardial cells. Life Sci 1995;57:1925-1934.
67. Occhipinti R, Somersalo E, Calvetti D. Astrocytes as the glucose shunt for glutamatergic neurons at high activity: an in silico study. J Neurophysiol 2009;101:2528-2538.
68. Carafoli E, Lehninger AL. Binding of adenine nucleotides by mitochondria during active uptake of CA++. Biochem Biophys Res Commun 1964;16:66-70.
69. Palty R, Silverman WF, Hershfinkel M, Caporale T, Sensi SL, Parnis J et al. NCLX is an essential component of mitochondrial Na+/Ca2+ exchange. Proc Natl Acad Sci USA 2010;107:436-441.
70. Denton RM. Regulation of mitochondrial dehydrogenases by calcium ions. Biochim Biophys Acta 2009;1787:1309-1316.
71. Lewandowski ED, Yu X, LaNoue KF, White LT, Doumen C, O'Donnell JM. Altered metabolite exchange between subcellular compartments in intact postischemic rabbit hearts. Circ Res 1997;81:165-175. (Pubitemid 27342483)
72. O'Donnell JM, White LT, Lewandowski ED. Mitochondrial transporter responsiveness and metabolic flux homeostasis in postischemic hearts. Am J Physiol 1999; 277:H866-H873. (Pubitemid 29459598)
73. O'Donnell JM, Kudej RK, LaNoue KF, Vatner SF, Lewandowski ED. Limited transfer of cytosolic NADH into mitochondria at high cardiac workload. Am J Physiol Heart Circ Physiol 2004;286:H2237-H2242. (Pubitemid 38685238)
74. Contreras L, Satrustegui J. Calcium signaling in brain mitochondria: interplay of malate aspartate NADH shuttle and calcium uniporter/mitochondrial dehydrogenase pathways. J Biol Chem 2009;284:7091-7099.
75. Williamson JR, Safer B, LaNoue KF, Smith CM, Walajtys E. Mitochondrial-cytosolic interactions in cardiac tissue: role of the malate-aspartate cycle in the removal of glycolytic NADH from the cytosol. Symp Soc Exp Biol 1973;27:241-281.
76. Lu M, Zhou L, Stanley WC, Cabrera ME, Saidel GM, Yu X. Role of the malate-aspartate shuttle on the metabolic response to myocardial ischemia. J Theor Biol 2008;254:466-475.
77. Rasola A, Bernardi P. The mitochondrial permeability transition pore and its involvement in cell death and in disease pathogenesis. Apoptosis 2007;12:815-833. (Pubitemid 46653292)
78. Randle PJ, England PJ, Denton RM. Control of the tricarboxylate cycle and its interactions with glycolysis during acetate utilization in rat heart. Biochem J 1970;117: 677-695.
79. Ruiz-Meana M, Fernandez-Sanz C, Garcia-Dorado D. The SR-mitochondria interaction: a new player in cardiac pathophysiology. Cardiovasc Res 2010; 88:30-39.
80. Dorn GW II, Scorrano L. Two close, too close: sarcoplasmic reticulummitochondrial crosstalk and cardiomyocyte fate. Circ Res 2010;107:689-699.
81. del Monte F, Lebeche D, Guerrero JL, Tsuji T, Doye AA, Gwathmey JK et al. Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling. Proc Natl Acad Sci USA 2004;101:5622-5627. (Pubitemid 38481206)
82. Talukder MA, Yang F, Nishijima Y, Chen CA, Kalyanasundaram A, Periasamy M et al. Reduced SERCA2a converts sub-lethal myocardial injury to infarction and affects postischemic functional recovery. J Mol Cell Cardiol 2009;46:285-287.
83. Micheletti R, Palazzo F, Barassi P, Giacalone G, Ferrandi M, Schiavone A et al. Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure. Am J Cardiol 2007;99:24A-32A.
84. Lee KW, Ladinsky H, Stuckey JH. Decreased Ca2+ uptake by sarcoplasmic reticulum after coronary artery occlusion for 60 and 90 minutes. Circ Res 1967;21: 439-444.
85. Zucchi R, Ronca-Testoni S, Di Napoli P, Yu G, Gallina S, Bosco G et al. Sarcoplasmic reticulum calcium uptake in human myocardium subjected to ischemia and reperfusion during cardiac surgery. J Mol Cell Cardiol 1996;28:1693-1701. (Pubitemid 26300569)
86. Garcia-Rivas G, de J, Carvajal K, Correa F, Zazueta C. Ru360, a specific mitochondrial calcium uptake inhibitor, improves cardiac post-ischaemic functional recovery in rats in vivo. Br J Pharmacol 2006;149:829-837. (Pubitemid 44851707)
87. Bar FW, Tzivoni D, Dirksen MT, Fernandez-Ortiz A, Heyndrickx GR, Brachmann J et al. Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-Elevation Myocardial Infarction: the randomized multicentre CASTEMI study. Eur Heart J 2006;27: 2516-2523. (Pubitemid 44627293)
88. Tzivoni D, Balkin J, Bar FW, Hibberd M, Reiber JH, Cowing G. Effect of caldaret on the incidence of severe left ventricular dysfunction in patients with ST-elevation myocardial infarction undergoing primary coronary intervention. Am J Cardiol 2009;103:1-4.
89. Cohen MV, Yang XM, Downey JM. The pH hypothesis of postconditioning: staccato reperfusion reintroduces oxygen and perpetuates myocardial acidosis. Circulation 2007;115:1895-1903. (Pubitemid 46598903)
90. Vinten-Johansen J, Zhao ZQ, Jiang R, Zatta AJ, Dobson GP. Preconditioning and postconditioning: innate cardioprotection from ischemia-reperfusion injury. J Appl Physiol 2007;103:1441-1448. (Pubitemid 47605986)
91. Kevin LG, Camara AK, Riess ML, Novalija E, Stowe DF. Ischemic preconditioning alters real-time measure of O2 radicals in intact hearts with ischemia and reperfusion. Am J Physiol Heart Circ Physiol 2003;284:H566-H574. (Pubitemid 36142884)
92. Ozcan C, Bienengraeber M, Dzeja PP, Terzic A. Potassium channel openers protect cardiac mitochondria by attenuating oxidant stress at reoxygenation. Am J Physiol Heart Circ Physiol 2002;282:H531-H539. (Pubitemid 34654976)
93. Hausenloy DJ, Wynne AM, Yellon DM. Ischemic preconditioning targets the reperfusion phase. Basic Res Cardiol 2007;102:445-452. (Pubitemid 47278817)
94. O'Donnell JM, Pound K, Xu X, Lewandowski ED. SERCA1 expression enhances the metabolic efficiency of improved contractility in post-ischemic heart. J Mol Cell Cardiol 2009;47:614-621.
95. Finegan BA, Lopaschuk GD, Gandhi M, Clanachan AS. Ischemic preconditioning inhibits glycolysis and proton production in isolated working rat hearts. Am J Physiol 1995;269:H1767-H1775. (Pubitemid 3005974)
96. Vogt AM, Poolman M, Ackermann C, Yildiz M, Schoels W, Fell DA et al. Regulation of glycolytic flux in ischemic preconditioning. A study employing metabolic control analysis. J Biol Chem 2002;277:24411-24419. (Pubitemid 34951964)
97. Bradamante S, Marchesani A, Barenghi L, Paracchini L, de Jonge R, de Jong JW. Glycogen turnover and anaplerosis in preconditioned rat hearts. Biochim Biophys Acta 2000;1502:363-379.
98. Vaughan-Jones RD, Spitzer KW, Swietach P. Intracellular pH regulation in heart. J Mol Cell Cardiol 2009;46:318-331.
99. Inserte J, Garcia-Dorado D, Ruiz-Meana M, Padilla F, Barrabes JA, Pina P et al. Effect of inhibition of Na(+)/Ca(2+) exchanger at the time of myocardial reperfusion on hypercontracture and cell death. Cardiovasc Res 2002;55:739-748.
100. Ruiz-Meana M, Abellan A, Miro-Casas E, Garcia-Dorado D. Opening of mitochondrial permeability transition pore induces hypercontracture in Ca2+ overloaded cardiac myocytes. Basic Res Cardiol 2007;102:542-552. (Pubitemid 47578399)
101. Inserte J, Ruiz-Meana M, Rodriguez-Sinovas A, Barba I, Garcia-Dorado D. Contribution of delayed intracellular pH recovery to ischemic postconditioning protection. Antioxid Redox Signal 2011;14:923-939.
102. Terrand J, Papageorgiou I, Rosenblatt-Velin N, Lerch R. Calcium-mediated activation of pyruvate dehydrogenase in severely injured postischemic myocardium. Am J Physiol Heart Circ Physiol 2001;281:H722-H730.
103. Wambolt RB, Lopaschuk GD, Brownsey RW, Allard MF. Dichloroacetate improves postischemic function of hypertrophied rat hearts. J Am Coll Cardiol 2000;36: 1378-1385.
104. Olson AK, Hyyti OM, Cohen GA, Ning XH, Sadilek M, Isern N et al. Superior cardiac function via anaplerotic pyruvate in the immature swine heart after cardiopulmonary bypass and reperfusion. Am J Physiol Heart Circ Physiol 2008;295:H2315-H2320.
105. Pound KM, Sorokina N, Ballal K, Berkich DA, Fasano M, Lanoue KF et al. Substrate-enzyme competition attenuates upregulated anaplerotic flux through malic enzyme in hypertrophied rat heart and restores triacylglyceride content: attenuating upregulated anaplerosis in hypertrophy. Circ Res 2009;104:805-812.
106. Panchal AR, Comte B, Huang H, Kerwin T, Darvish A, des Rosiers C et al. Partitioning of pyruvate between oxidation and anaplerosis in swine hearts. Am J Physiol Heart Circ Physiol 2000;279:H2390-H2398.
107. Panchal AR, Comte B, Huang H, Dudar B, Roth B, Chandler M et al. Acute hibernation decreases myocardial pyruvate carboxylation and citrate release. Am J Physiol Heart Circ Physiol 2001;281:H1613-H1620.
108. Young VR, Ajami AM. Glutamate: an amino acid of particular distinction. J Nutr 2000; 130:892S-900S. (Pubitemid 30173612)
109. Kimose HH, Helligso P, Randsbaek F, Kim Y, Botker HE, Hansen SB et al. Improved recovery after cold crystalloid cardioplegia using low-dose glutamate enrichment during reperfusion after aortic unclamping: a study in isolated blood-perfused pig hearts. Thorac Cardiovasc Surg 1996;44:118-125. (Pubitemid 26246964)
110. Pereda D, Castella M, Pomar JL, Cartana R, Josa M, Barriuso C et al. Elective cardiac surgery using Celsior or St. Thomas No. 2 solution: a prospective, single-center, randomized pilot study. Eur J Cardiothorac Surg 2007;32:501-506. (Pubitemid 47223718)
111. Mudge GH Jr, Mills RM Jr, Taegtmeyer H, Gorlin R, Lesch M. Alterations of myocardial amino acid metabolism in chronic ischemic heart disease. J Clin Invest 1976;58: 1185-1192.
112. Dinkelborg LM, Kinne RK, Grieshaber MK. Transport and metabolism of L-glutamate during oxygenation, anoxia, and reoxygenation of rat cardiac myocytes. Am J Physiol 1996;270:H1825-H1832.
113. Tsai PJ, Huang PC. Circadian variations in plasma and erythrocyte glutamate concentrations in adult men consuming a diet with and without added monosodium glutamate. J Nutr 2000;130:1002S-1004S.
114. Schaumburg HH, Byck R, Gerstl R, Mashman JH. Monosodium L-glutamate: its pharmacology and role in the Chinese restaurant syndrome. Science 1969;163: 826-828.
115. Thomassen A, Nielsen TT, Bagger JP, Henningsen P. Effects of intravenous glutamate on substrate availability and utilization across the human heart and leg. Metabolism 1991;40:378-384.
116. Laughlin MR, Taylor J, Chesnick AS, DeGroot M, Balaban RS. Pyruvate and lactate metabolism in the in vivo dog heart. Am J Physiol 1993;264:H2068-H2079. (Pubitemid 23205978)
117. Weinberg JM, Venkatachalam MA, Roeser NF, Nissim I. Mitochondrial dysfunction during hypoxia/reoxygenation and its correction by anaerobic metabolism of citric acid cycle intermediates. Proc Natl Acad Sci USA 2000;97:2826-2831. (Pubitemid 30159256)
118. Wiesner RJ, Deussen A, Borst M, Schrader J, Grieshaber MK. Glutamate degradation in the ischemic dog heart: contribution to anaerobic energy production. J Mol Cell Cardiol 1989;21:49-59. (Pubitemid 19078692)
119. Sherry AD, Zhao P, Wiethoff AJ, Jeffrey FM, Malloy CR. Effects of aminooxyacetate on glutamate compartmentation and TCA cycle kinetics in rat hearts. Am J Physiol 1998;274:H591-H599.
120. Kristiansen SB, Lüfgren B, Stüttrup NB, Kimose HH, Nielsen-Kudsk JE, Botker HE et al. Cardioprotection by L-glutamate during postischaemic reperfusion: reduced infarct size and enhanced glycogen resynthesis in a rat insulin-free heart model. Clin Exp Pharmacol Physiol 2008;35:884-888. (Pubitemid 351951935)
121. Stüttrup NB, Kristiansen SB, Lüfgren B, Hansen BF, Kimose HH, Botker HE et al. L-glutamate and glutamine improve haemodynamic function and restore myocardial glycogen content during postischaemic reperfusion: a radioactive tracer study in the rat isolated heart. Clin Exp Pharmacol Physiol 2006;33:1099-1103. (Pubitemid 44581574)
122. Swanson RA, Choi DW. Glial glycogen stores affect neuronal survival during glucose deprivation in vitro. J Cereb Blood Flow Metab 1993;13:162-169. (Pubitemid 23016613)
123. Hamai M, Minokoshi Y, Shimazu T. L-Glutamate and insulin enhance glycogen synthesis in cultured astrocytes from the rat brain through different intracellular mechanisms. J Neurochem 1999;73:400-407. (Pubitemid 29289149)
124. Gincel D, Shoshan-Barmatz V. Glutamate interacts with VDAC and modulates opening of the mitochondrial permeability transition pore. J Bioenerg Biomembr 2004;36:179-186. (Pubitemid 39023635)
125. Feldkamp T, Weinberg JM, Horbelt M, Von Kropff C, Witzke O, Nurnberger J et al. Evidence for involvement of nonesterified fatty acid-induced protonophoric uncoupling during mitochondrial dysfunction caused by hypoxia and reoxygenation. Nephrol Dial Transplant 2009;24:43-51.
126. Feldkamp T, Park JS, Pasupulati R, Amora D, Roeser NF, Venkatachalam MA et al. Regulation of the mitochondrial permeability transition in kidney proximal tubules and its alteration during hypoxia-reoxygenation. Am J Physiol Renal Physiol 2009; 297:F1632-F1646.
127. Williams H, King N, Griffiths EJ, Suleiman MS. Glutamate-loading stimulates metabolic flux and improves cell recovery following chemical hypoxia in isolated cardiomyocytes. J Mol Cell Cardiol 2001;33:2109-2119. (Pubitemid 34073054)
128. King N, McGivan JD, Griffiths EJ, Halestrap AP, Suleiman MS. Glutamate loading protects freshly isolated and perfused adult cardiomyocytes against intracellular ROS generation. J Mol Cell Cardiol 2003;35:975-984. (Pubitemid 36871022)
129. Jessen ME, Kovarik TE, Jeffrey FM, Sherry AD, Storey CJ, Chao RY et al. Effects of amino acids on substrate selection, anaplerosis, and left ventricular function in the ischemic reperfused rat heart. J Clin Invest 1993;92:831-839. (Pubitemid 23262405)
130. Suleiman MS, Dihmis WC, Caputo M, Angelini GD, Bryan AJ. Changes in myocardial concentration of glutamate and aspartate during coronary artery surgery. Am J Physiol 1997;272:H1063-H1069.
131. Johns L, Sinclair AJ, Davies JA. Hypoxia/hypoglycemia-induced amino acid release is decreased in vitro by preconditioning. Biochem Biophys Res Commun 2000;276: 134-136.
132. Castillo J, Davalos A, Noya M. Progression of ischaemic stroke and excitotoxic aminoacids. Lancet 1997;349:79-83. (Pubitemid 27023423)
133. Kovacevic Z, McGivan JD. Mitochondrial metabolism of glutamine and glutamate and its physiological significance. Physiol Rev 1983;63:547-605. (Pubitemid 13134309)
134. Khogali SE, Harper AA, Lyall JA, Rennie MJ. Effects of L-glutamine on post-ischaemic cardiac function: protection and rescue. J Mol Cell Cardiol 1998;30:819-827. (Pubitemid 28190726)
135. Liu J, Marchase RB, Chatham JC. Glutamine-induced protection of isolated rat heart from ischemia/reperfusion injury is mediated via the hexosamine biosynthesis pathway and increased protein O-GlcNAc levels. J Mol Cell Cardiol 2007;42:177-185. (Pubitemid 44958621)
136. Laczy B, Hill BG, Wang K, Paterson AJ, White CR, Xing D et al. Protein O-GlcNAcylation: a new signaling paradigm for the cardiovascular system. Am J Physiol Heart Circ Physiol 2009;296:H13-H28.
137. Ngoh GA, Facundo HT, Zafir A, Jones SP. O-GlcNAc signaling in the cardiovascular system. Circ Res 2010;107:171-185.
138. Wells L, Vosseller K, Hart GW. Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science 2001;291:2376-2378. (Pubitemid 32231793)
139. Wu G, Haynes TE, Li H, Yan W, Meininger CJ. Glutamine metabolism to glucosamine is necessary for glutamine inhibition of endothelial nitric oxide synthesis. Biochem J 2001;353:245-252. (Pubitemid 32096932)
140. Jones SP, Zachara NE, Ngoh GA, Hill BG, Teshima Y, Bhatnagar A et al. Cardioprotection by N-acetylglucosamine linkage to cellular proteins. Circulation 2008;117: 1172-1182. (Pubitemid 351544067)
141. Watson LJ, Facundo HT, Ngoh GA, Ameen M, Brainard RE, Lemma KM et al. O-linked b-N-acetylglucosamine transferase is indispensable in the failing heart. Proc Natl Acad Sci USA 2010;107:17797-17802.
142. Hamiel CR, Pinto S, Hau A, Wischmeyer PE. Glutamine enhances heat shock protein 70 expression via increased hexosamine biosynthetic pathway activity. Am J Physiol Cell Physiol 2009;297:C1509-C1519.
143. Wischmeyer PE, Jayakar D, Williams U, Singleton KD, Riehm J, Bacha EA et al. Single dose of glutamine enhances myocardial tissue metabolism, glutathione content, and improves myocardial function after ischemia-reperfusion injury. JPEN J Parenter Enteral Nutr 2003;27:396-403. (Pubitemid 38133103)
144. Cheung MM, Kharbanda RK, Konstantinov IE, Shimizu M, Frndova H, Li J et al. Randomized controlled trial of the effects of remote ischemic preconditioning on children undergoing cardiac surgery: first clinical application in humans. J Am Coll Cardiol 2006;47:2277-2282. (Pubitemid 43795071)
145. Botker HE, Kharbanda R, Schmidt MR, Bottcher M, Kaltoft AK, Terkelsen CJ et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 2010;375:727-734.
146. Weitzel LR, Wischmeyer PE. Glutamine in critical illness: the time has come, the time is now. Crit Care Clin 2010;26:515-525.